India Eye Drop Market, By Type (Prescription, Over the Counter), By Drug Class (Antiallergy, Anti-inflammatory, Antiglaucoma, Anti-VEGF, Others), By Disease Indication (Dry Eye Diseases, Glaucoma, Eye Allergy, Eye Infections, Retinal Disorders, Others), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Eye Drop Market was valued at USD 500.07 Million in 2024 and is anticipated to reach USD 638.64 Million by 2030, with a CAGR of 4.12% during 2025-2030. The market is witnessing growth, driven by key factors such as an aging population, rising incidences of eye disorders, increased awareness of eye health, and advancements in pharmaceutical technology. Both prescription and over-the-counter (OTC) eye drops are seeing heightened demand across various segments, including treatments for allergies, infections, dry eye, and other ocular conditions.

The market is set for sustained expansion, fueled by ongoing urbanization, improvements in healthcare infrastructure, and broader insurance coverage. Companies that prioritize affordability, innovation, and efficient distribution strategies will be well-positioned to leverage this growth. Additionally, international collaborations and investments in local manufacturing will be critical in shaping market dynamics over the coming decade.

Key Report Takeaway

• Over the counter eye drops led by type in 2024, supported by easy retail and online access, self care trends, and rising screen related eye concerns
• Broad product range including preservative free, multi dose, lubricating, redness relief, and allergy specific drops increased consumer adoption
• Antiallergy drug class projected strong growth, driven by rising pollution, higher allergen exposure, and increasing cases of allergic conjunctivitis
• North India held the largest share in 2024, supported by dense urban population, strong healthcare infrastructure, higher premium product uptake, and regional pharmaceutical manufacturing hubs

Key Market Drivers

Aging Population and Rising Prevalence of Age-Related Eye Disorders

India’s aging population is a central growth driver for the eye drop segment. It is estimated that 13.2 percent of the population will be over 60 by 2031, rising to 19 percent by 2050. This demographic shift is consistently reflected in Government of India and UNFPA ageing projections and directly expands the pool at risk for cataracts, glaucoma, presbyopia, and dry eye that often require ongoing drop therapy. As life expectancy improves, age-related eye disorders are becoming more common. Cataracts, glaucoma, macular degeneration, and presbyopia affect a large share of older adults and often require ongoing treatment. Glaucoma management depends on long-term pressure-lowering drops, while cataract procedures involve preoperative and postoperative medication support.

Most age-related eye diseases are chronic and progressive, requiring daily and sustained therapy. Elderly patients often use multiple formulations, including antiglaucoma, anti-inflammatory, antibiotic, and lubricating drops. This repeated usage creates stable and recurring demand. Public health efforts, including the National Programme for Control of Blindness and Visual Impairment, promote early screening and treatment, increasing awareness and prescription rates. This government-led screening and referral push supports earlier diagnosis and longer duration of therapy, which increases repeat dispensing of chronic eye drops through hospitals and retail pharmacies. Regular eye check-ups and early diagnosis are expanding the treated patient pool across urban and semi-urban regions.

Cataracts remain a leading cause of blindness in India, with over 6.5 million surgeries conducted annually through a mix of public programs and large private eye-care networks. Each procedure requires weeks of postoperative care using steroid, antibiotic, and anti-inflammatory drops. Dry eye syndrome is also rising among the elderly, often linked to reduced tear production and environmental exposure. Artificial tears and preservative-free lubricants are seeing higher adoption as patients seek comfort and preventive care. High-volume Indian eye-care providers, including major private hospital groups and dedicated eye-care systems, typically follow standardized post-operative drop regimens, reinforcing consistent demand for therapeutic and supportive eye drops. As older consumers focus on vision quality and long-term eye health, sustained demand for therapeutic and supportive eye drops is expected to continue.

Urbanization and Increased Digital Screen Exposure

Rapid urbanization and rising digital device use are reshaping eye care demand in India. Nearly 600 million people are expected to live in cities by 2030, increasing exposure to pollution, artificial lighting, and screen-heavy work patterns. Urban air contains dust and particulate matter that trigger allergic conjunctivitis, dryness, and irritation. Longer work hours, stress, and reduced outdoor activity also contribute to eye strain and fatigue. These factors are increasing reliance on OTC drops for redness, allergies, and moisture support. India’s National Health Accounts 2019 to 20 estimates OTC medicines at 3.47 percent of current health expenditure, indicating significant reliance on retail self-care purchases that can include OTC eye drops for minor symptoms.

Digital screen exposure has become routine across age groups, from office workers to school students. Prolonged screen use reduces blink rate, leading to tear film instability and chronic dry eye symptoms. Digital eye strain, often called computer vision syndrome, presents with blurred vision, headaches, and ocular discomfort. Artificial tears and lubricating drops are widely used to relieve dryness and restore comfort. Blue light exposure from devices adds to visual fatigue, encouraging preventive and symptomatic use of hydrating formulations. Rural Health Statistics 2021 to 22 reports a 79.5 percent shortfall of specialists at rural Community Health Centres, which can reinforce pharmacy-led, symptom-driven use of OTC products when quick access to specialist eye care is limited.

Younger consumers are now active participants in this segment, expanding the customer base beyond older adults. Online learning, gaming, and remote work have increased daily screen hours among youth. Pollution levels in cities such as Delhi, Mumbai, and Bangalore intensify eye irritation, especially during peak smog periods. Antihistamine and lubricating drops see seasonal spikes as air quality declines. As urban lifestyles and digital habits deepen, steady demand for symptomatic and preventive eye care products is expected to continue. Government of India LASI Wave 1 2017 to 2018 reports 43.4 percent of Indians aged 60 years and above consumed some medicine without consulting a health professional, reflecting an established self-care tendency that can also support OTC eye-drop use for transient discomfort.

Rising Incidence of Diabetes and Related Eye Conditions

India has around 77 million adults with type 2 diabetes and nearly 25 million prediabetics. Uncontrolled blood sugar damages retinal vessels, leading to diabetic retinopathy and vision loss risk. Nearly 30 percent of diabetic patients are vulnerable to this complication, requiring ongoing ophthalmic care. Treatment often includes anti-VEGF injections, supported by steroid and anti-inflammatory eye drops to manage swelling and post-procedure irritation. As screening improves and diagnosis rates rise, demand for prescription and OTC eye drops continues to expand.

Diabetic macular edema, a progression of retinopathy, causes fluid buildup in the macula and impairs sharp vision. Management requires repeated clinical intervention and long-term medication support. Patients frequently use steroid formulations after intravitreal therapy and lubricating drops for comfort. Chronic disease management increases repeat purchases, strengthening steady consumption patterns in this segment. As diabetes prevalence grows across urban and semi-urban populations, the treated patient base widens.

Diabetes also disrupts tear production and nerve function, leading to diabetic dry eye syndrome. Persistent dryness, irritation, and inflammation increase reliance on artificial tears and preservative-free lubricants. Weakened immunity raises the risk of infections such as conjunctivitis and keratitis, increasing need for antibiotic and anti-inflammatory drops. As metabolic disorders rise nationwide, sustained use of therapeutic and supportive eye medications is expected to remain strong.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles and Compliance Complexities

Regulatory complexity remains a key constraint for India’s eye drop segment. Ophthalmic products are regulated by the Central Drugs Standard Control Organization, which mandates detailed data on safety, efficacy, and stability. Approval timelines for new formulations can be prolonged, delaying product launches and slowing innovation cycles. As eye drops are sterile products, manufacturers must maintain controlled environments, validated processes, and strict quality assurance systems. These requirements increase operational costs, especially for small and mid-sized firms.

Compliance burdens extend beyond central approvals. India’s pharmaceutical landscape is fragmented across states, where documentation standards and enforcement practices may vary. Companies often face procedural delays and additional administrative steps when expanding distribution networks. This uneven regulatory framework complicates market entry and scale-up strategies.

High compliance costs and lengthy review processes create entry barriers for emerging players. Smaller manufacturers may struggle to fund clinical validation, facility upgrades, and ongoing inspections. As a result, introduction of advanced or premium formulations becomes slower, limiting product diversification. Over time, these regulatory hurdles can restrain innovation and moderate the overall growth pace of the segment.

Market Fragmentation and Intense Competition

The India eye drop segment is highly fragmented, with multinational firms, large domestic companies, and small regional manufacturers competing side by side. The country remains price sensitive, especially in OTC categories such as artificial tears and redness relief drops. Intense competition often results in aggressive price cuts, particularly among smaller players seeking faster volume growth. This environment compresses margins and makes it difficult for companies to sustain premium positioning or introduce specialized formulations at higher price points.

Product differentiation is limited in many OTC segments, where formulations contain similar active ingredients. As offerings appear comparable, purchasing decisions are often driven by price rather than brand preference or added features. This commoditization reduces brand loyalty and increases promotional spending pressure. Companies must balance affordability with quality assurance, which can strain profitability over time.

A sizeable informal sector further complicates the competitive landscape. Unregulated or loosely monitored manufacturers sell low-cost alternatives that attract price-conscious consumers. While these products may not follow the same compliance standards, they create downward pricing pressure on organized players. As firms focus on defending market share, investment in research, product innovation, and brand building may decline, affecting long-term value creation.

Key Market Trends

Rising Demand for Premium and Specialty Eye Drops

Demand for premium and specialty eye drops is rising among urban and higher-income consumers. Greater health awareness and access to specialist care are encouraging adoption of advanced formulations. Patients increasingly seek preservative-free, single-use, and multi-dose systems that improve safety and comfort. Targeted therapies for allergy-related conjunctivitis, severe dry eye, and post-surgical recovery are gaining traction in metropolitan areas. This shift is gradually increasing value contribution from specialized products.

Therapeutic drops containing immune-modulating agents such as cyclosporine for chronic dry eye are seeing higher prescriptions. Anti-inflammatory formulations, including NSAID and steroid-based drops, are widely used after cataract and refractive procedures. As surgical volumes increase, demand for high-efficacy postoperative care products is also expanding. Consumers are more informed about long-term eye health, leading to greater acceptance of premium pricing when outcomes are clear.

Interest in natural and herbal formulations is also growing, influenced by preventive health trends. Products aligned with traditional systems such as Ayurveda are attracting consumers who prefer plant-based solutions. Urban buyers often prioritize quality, safety, and convenience over price alone. This evolution in preferences is encouraging pharmaceutical companies to broaden portfolios with differentiated, higher-value offerings.

Telemedicine and Digital Health Integration for Eye Care

The growing adoption of telemedicine and digital health platforms is significantly impacting how eye care is delivered in India. As technology plays a larger role in healthcare, the integration of teleophthalmology services is changing how consumers access eye care products, including eye drops. This trend is driven by a combination of increased internet penetration, the expansion of digital healthcare solutions, and the rising need for remote consultation in a vast and diverse country like India.

Telemedicine platforms are enabling eye care consultations to be conducted remotely, particularly in regions where access to ophthalmologists and eye care specialists is limited. Patients can now receive virtual eye exams and diagnoses for common eye conditions such as dry eyes, infections, or allergic reactions. This increases the demand for eye drops, as patients can easily obtain e-prescriptions following their remote consultations. The rise of online pharmacies and digital health platforms is reshaping the distribution model for eye care products. Consumers are increasingly purchasing eye drops through e-commerce channels, driven by the convenience of home delivery, ease of comparison shopping, and access to a wider range of products. This is particularly relevant in urban areas where busy lifestyles make online shopping more appealing.

Artificial intelligence (AI)-based tools are being integrated into eye health diagnostics, offering patients more accessible screening and monitoring for conditions like glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD). These tools can detect early signs of eye diseases, prompting patients to take preventive measures, including the use of eye drops to manage or slow disease progression.

Segmental Insights

Type Insights

Based on the category of type, the over-the-counter segment emerged as the dominant in the market for eye drop in 2024. OTC eye drops are widely available in pharmacies, supermarkets, and online platforms, making them easily accessible to consumers. This convenience attracts a broader demographic, including those who may not seek professional medical advice for mild eye conditions such as dry eyes, allergies, and irritation. The ability to self-diagnose and purchase OTC products without a prescription significantly enhances market penetration. Increasing awareness of eye health and the impact of lifestyle factors (such as prolonged screen time) has led consumers to proactively seek solutions for common issues. This trend has resulted in higher sales of OTC eye drops designed for lubrication, redness relief, and allergy management.

The OTC segment has seen a diversification of product offerings, including preservative-free options, multi-dose systems, and natural formulations. Manufacturers are also introducing specialized products targeting specific conditions, such as artificial tears for dry eye syndrome and antihistamine drops for allergy relief. This variety caters to different consumer needs and preferences, driving growth in the OTC market. The growth of e-commerce platforms has made it easier for consumers to access a wide range of OTC eye drops. Online pharmacies are increasingly popular, offering competitive pricing, home delivery, and extensive product choices. This trend contributes to the rising sales of OTC products, particularly among tech-savvy consumers who prefer the convenience of online shopping. These factors are expected to drive the growth of this segment.

Drug Class Insights

The Antiallergy segment is projected to experience rapid growth during the forecast period. With rising pollution levels, changing weather patterns, and increased exposure to allergens such as dust, pollen, and pet dander, the incidence of allergic conjunctivitis has surged. This condition is particularly common in urban areas, driving demand for antiallergy eye drops, which provide relief from symptoms like itching, redness, and swelling. Antiallergy eye drops appeal to a broad demographic, including children and adults alike. The availability of various formulations, including antihistamines, mast cell stabilizers, and combination products, ensures that there are effective solutions for different types of allergic reactions.

Growing awareness of eye allergies and their management has led consumers to seek over-the-counter antiallergy eye drops without requiring a prescription. This trend is further fueled by educational campaigns that highlight the importance of eye health, thereby increasing the segment's market share. Ongoing research and development in the antiallergy category have led to the introduction of more effective formulations, including preservative-free options that are gentler on the eyes. This innovation continues to drive consumer preference toward antiallergy products. These factors collectively contribute to the segment's growth.

Download Free Sample Report

Regional Insights

North India emerged as the dominant in the eye drop market in 2024, holding the largest market share in terms of value. The Northern region hosts some of the most densely populated cities, such as Delhi NCR, where urbanization and industrialization are significantly higher. These urban centers drive up the demand for eye drops, particularly for conditions like dry eyes, allergies, and infections due to increased pollution and screen exposure in urban lifestyles.

This region benefits from a well-established healthcare infrastructure, with access to numerous hospitals, clinics, and pharmacies. Consumers in this region are more likely to seek timely medical attention, leading to higher prescription rates for eye care products. Additionally, large ophthalmic hospitals and clinics, particularly in Delhi, are key drivers of demand for both prescription and over-the-counter (OTC) eye drops.

Northern India has a relatively higher proportion of affluent consumers who are more likely to purchase premium eye care products and seek advanced treatments for conditions like presbyopia, glaucoma, and age-related macular degeneration (AMD). This drives up the demand for specialty eye drops, such as those for post-surgical care or chronic eye conditions. States like Himachal Pradesh and Uttarakhand are major hubs for pharmaceutical manufacturing. Their proximity to the Northern markets ensures an efficient supply chain, allowing for quicker distribution and availability of a wide range of eye care products in this region.

Recent Developments

• In February 2026, a CDSCO Subject Expert Committee (Ophthalmology) meeting record noted a firm presentation seeking permission to import an investigational product described as “Sodium hyaluronate 0.2% eye drop" reflecting ongoing pipeline activity for new eye-drop formulations in India.
• In January 2026, ENTOD Pharmaceuticals announced it developed what it described as the world’s first losartan-based eye drops for corneal scarring (brand referenced as “Ocuzart”), positioning it as a new ophthalmic formulation aimed at corneal healing/anti‑scarring.
• In September 2024, The Drugs Controller General of India (DCGI) granted final approval to ENTOD Pharmaceuticals for its PresVu eye drops, designed to reduce the need for reading glasses in individuals with presbyopia. This age-related vision condition, commonly affecting those over 40, leads to difficulty focusing on close objects. PresVu offers an innovative solution for managing presbyopia and represents a significant advancement in eye care for older adults.  

Key Market Players

• CiplaLimited
• Alcon Laboratories (India) Pvt. Ltd.
• AbbVie Inc.
• Bausch & Lomb Pvt Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Lupin Limited
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Torrent Pharmaceuticals Ltd

Report Scope:

In this report, the India Eye Drop Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Eye Drop Market, By Type:

o   Prescription

o   Over the Counter

• India Eye Drop Market, By Drug Class:

o   Antiallergy

o   Anti-inflammatory

o   Antiglaucoma

o   Anti-VEGF

o   Others

• India Eye Drop Market, By Disease Indication:

o   Dry Eye Diseases

o   Glaucoma

o   Eye Allergy

o   Eye Infections

o   Retinal Disorders

o   Others

• India Eye Drop Market, By Distribution Channel:

o   Hospitals Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

• India Eye Drop Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Eye Drop Market.

Available Customizations:

 India Eye Drop market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

 India Eye Drop Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]